

**Freedom of Information (Scotland) Act 2002**  
**Environmental Information (Scotland) Regulations 2004**

<b>Date received</b>	22/11/22	<b>Subject</b>	Olaparib Patient Initiations	
<b>Date passed</b>	22/11/22	<b>Respond by</b>	13/12/22	
<b>Passed to</b>	Pharmacy Oncology Nurses		<b>FOI number</b>	2022-536
<b>Category of information requested</b>	H&SC Delivery - Assessment / Diagnosis / Treatment			

**Question/s to be answered**

Please may you tell me how many patient initiations were recorded from January 2019 to October 2022, monthly and moving annual total (i.e. Nov-21 to Oct-22) for:

1. Olaparib (Lynparza®) capsules as monotherapy (SMC No. 1047/15) for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy (November 2016)

0

2. Olaparib (Lynparza®) tablets as monotherapy (SMC2209) for the maintenance treatment of adult patients with newly diagnosed advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first line platinum-based chemotherapy (December 2019)

0

3. Olaparib (Lynparza®) tablets as monotherapy (SMC2367) for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy (August 2021)

0

4. Olaparib (Lynparza®) tablets in combination with bevacizumab (SMC2368) for the maintenance treatment of adults with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (December 2021)

0

5. Olaparib (Lynparza®) as monotherapy (SMC2366) for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or

**Freedom of Information (Scotland) Act 2002**

**Environmental Information (Scotland) Regulations 2004**

somatic) who have progressed following prior therapy that included a new hormonal agent (October 2021)

0